(Q38031146)

27 August 2017

title

Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group (English)

1 reference

27 August 2017

1 reference

acute myeloid leukemia

1 reference

Shuichi Miyawaki

1

1 reference

27 August 2017

publication date

2 August 2012

1 reference

International Journal of Hematology

27 August 2017

published in

1 reference

27 August 2017

volume

96

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

171-177

1 reference

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

Anthracycline dose intensification in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Grup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1150-6

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

12 December 2020

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

1 reference

12 December 2020

Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group

1 reference

12 December 2020

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

1 reference

12 December 2020

Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia

1 reference

12 December 2020

Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group

1 reference

12 December 2020

Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

1 reference

12 December 2020

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

12 December 2020

No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group

1 reference

12 December 2020

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

1 reference

12 December 2020

Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study

1 reference

12 December 2020

A randomized study of high-dose cytarabine in induction in acute myeloid leukemia

1 reference

12 December 2020

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group

1 reference

12 December 2020

10.1007/S12185-012-1150-6

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1040401215

0 references

1 reference